Skip to main content
Premium Trial:

Request an Annual Quote

Biocept: Michael Dugan, Nathaniel Sweed

Biocept has terminated the employment of Michael Dugan, its CMO and medical director, effective March 17, the firm said in a document filed with the US Securities and Exchange Commission. Biocept gave no reason for the action but said it has promoted Associate Medical Director Nathaniel Sweed to medical director and designated an undisclosed new medical director of the company's CLIA-certified, CAP-accredited clinical lab in San Diego. Dugan joined Biocept in August 2020.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.